Reference
Mikala G, et al. Minimal residual disease negativity after molecularly targeted venetoclax therapy of secondary plasma cell leukemia with translocation T(11;14). HemaSphere 2 (Suppl. 1): 994 abstr. PB2233, 14 Jun 2018. Available from: URL: http://doi.org/10.1097/HS9.0000000000000060 [abstract] - Hungary
Rights and permissions
About this article
Cite this article
Antineoplastics/clarithromycin. Reactions Weekly 1738, 39 (2019). https://doi.org/10.1007/s40278-019-57413-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-57413-3